| abstract |
Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form which provides for a rapid dispersion of the active substance in the oral cavity. Thereby, desmopressin may be absorbed across the sublingual, buccal and/or gingival mucosa, and/or from the gastrointestinal tract for systemic distribution. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. A process for the production of the dosage form by subliming solvent from a composition comprising desmopressin and a solution of carrier material is also provided. |